Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influencing blood usage in Germany: what is optimal use?
Schramm W, Berger K. Schramm W, et al. Transfusion. 2007 Aug;47(2 Suppl):152S-154S; discussion 155S-156S. doi: 10.1111/j.1537-2995.2007.01374.x. Transfusion. 2007. PMID: 17651341 No abstract available.
Blood component use and associated costs after standard dose chemotherapy--a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany.
Paessens B, Ihbe-Heffinger A, von Schilling C, Shlaen R, Bernard R, Peschel C, Schramm W, Berger K. Paessens B, et al. Among authors: schramm w. Support Care Cancer. 2012 May;20(5):1011-21. doi: 10.1007/s00520-011-1173-1. Epub 2011 May 12. Support Care Cancer. 2012. PMID: 21562801
Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W, Siebert U; European Haemophilia Economic Study Group. Lippert B, et al. Among authors: schramm w. Blood Coagul Fibrinolysis. 2005 Oct;16(7):477-85. doi: 10.1097/01.mbc.0000178830.39526.ff. Blood Coagul Fibrinolysis. 2005. PMID: 16175006
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.
Berger KC, Feldman BM, Wasserman J, Schramm W, Blanchette V, Fischer K; Outcome Measures Expert Working Group of the International Prophylaxis Study Group (IPSG). Berger KC, et al. Among authors: schramm w. Haematologica. 2016 Mar;101(3):266-8. doi: 10.3324/haematol.2015.139931. Haematologica. 2016. PMID: 26928247 Free PMC article. No abstract available.
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.
Peyvandi F, Berger K, Seitz R, Hilger A, Hecquet ML, Wierer M, Buchheit KH, O'Mahony B, Bok A, Makris M, Mansmann U, Schramm W, Mannucci PM. Peyvandi F, et al. Among authors: schramm w. Haematologica. 2020 Aug;105(8):2038-2043. doi: 10.3324/haematol.2019.242735. Epub 2020 May 28. Haematologica. 2020. PMID: 32467138 Free PMC article.
Are all licensed haemostatic agents for haemophilia therapy accessible to patients?
Berger K, Batorova A, Bohn R, di Minno M, Mannucci PM, Kavakli K, Schramm W, Aledort L; International Prophylaxis Study Group. Berger K, et al. Among authors: schramm w. Haemophilia. 2022 Nov;28(6):e256-e258. doi: 10.1111/hae.14660. Epub 2022 Sep 19. Haemophilia. 2022. PMID: 36122901 No abstract available.
[Health economic aspects of the use of blood and blood products].
Berger K, Frey L, Spannagl M, Schramm W. Berger K, et al. Among authors: schramm w. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):64-72. doi: 10.1007/s00103-005-1188-1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006. PMID: 16362134 German.
416 results